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A polymer coated cicaprost-eluting stent increases neointima formation and impairs vessel function in the 
rabbit iliac artery. 
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Abstract: 
Drug-eluting stents have been successful in reducing in-stent restenosis but are not suitable for all lesion types 
and have been implicated in causing late stent thrombosis due to incomplete regeneration of the endothelial cell 
layer. In this study we implanted stents coated with cicaprost, a prostacyclin analogue with a long plasma half-
life and antiproliferative effects on vascular smooth muscle cells, into the iliac arteries of rabbits. At 28 day 
follow-up we compared neointima formation within the stented vessels and vascular function in adjacent 
vessels, to assess if cicaprost could reduce restenosis without impairing vessel function.  Arteries implanted with 
cicaprost eluting stents had significantly more neointima compared to bare metal stents. In adjacent segments of 
artery, endothelium-dependent relaxation was impaired by the cicaprost-eluting stent but vasodilation to an 
endothelium-independent vasodilator was maintained. We conclude that the presence of the polymer and sub-
optimal release of cicaprost from the stent may be responsible for the increased neointma and impaired 
functional recovery of the endothelium observed. Further experiments should be aimed at optimising release of 
cicaprost and exploring different stent polymer coatings. 
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1. Introduction 
Drug-eluting stents have substantially reduced restenosis rates compared to bare metal stents [1]. They have 
overtaken coronary artery bypass graft (CABG) surgery as the main revascularisation method used for treatment 
of advanced coronary artery disease.  However, there is evidence that they do not perform as well as CABG in 
some cases, most notably in those patients with more than one diseased coronary artery [2] and or with existing 
co-morbidities [3]. Moreover, concerns remain around delayed healing and prolonged thrombosis risk [4], and 
although restenosis now occurs less frequently, it remains a clinical problem [5]. In addition, long term 
endothelial dysfunction in artery sections adjacent to implanted DES has also been reported [6-9]. 
Consequently, there is still a need to develop improved drug-eluting stents which retain the low restenosis rates 
of the current stents but do not impair endothelial recovery and compromise vessel function in the surrounding, 
non-stented region. 
 
In-stent restenosis (ISR) is a multifactorial cascade of events, where the outcome is the development of a 
neointima consisting of smooth muscle cells and extracellular matrix [10]. Balloon expansion and stent 
placement damage the endothelium leading to platelet adhesion, activation, and the generation of a thrombus 
[11]. The surface of the stent also causes activation of circulating neutrophils and macrophages within arterial 
tissue [12]. The release of cytokines and growth factors by transmigrated inflammatory cells activates smooth 
muscle cells and upregulation of matrix metalloproteinases leads to smooth muscle cell migration from the 
medial layer to the intimal layer. As new extracellular matrix is laid-down, a neointimal layer is formed which 
reduces lumen size [12]. 
 
Prostacyclin (PGI2) analogues are known to inhibit platelet activation [13] and smooth muscle cell proliferation 
in a variety of species, including humans [14,15]. Although the role of endogenous PGI2 in modulating 
inflammatory responses is complex [16], there is evidence that its analogues can inhibit leukocyte adhesion to 
endothelial cells [17]. Since these are two pivotal events in neointima formation, PGI2 analogues may represent 
promising candidates for incorporation within a novel DES. Indeed, the PGI2 analogue iloprost, in combination 
with the thrombin inhibitor hirudin, reduced neointima formation in the pig coronary artery [19]. However, the 
effect of iloprost alone was not reported, and no study to date has examined the effect of any locally delivered 
PGI2 analogue alone on neointima formation following stent-induced injury. In a previous study by our group 
we examined the vascular effects of various PGI2 analogues [19]. It was found that although AFP-07 was a more 
potent vasodilator than cicaprost, it induced an EP3 receptor-mediated contraction in the rabbit iliac artery at 
high concentrations. Both compounds had a moderate anti-proliferative effect on rabbit smooth muscle cells, 
which in the case of cicaprost was not modified by an EP receptor antagonist. Thus cicaprost, with its superior 
selectivity for IP receptors [20] may represent the more promising candidate drug for incorporation within a 
novel drug-eluting stent.  
 
Implantation of some drug-eluting stents can affect vasomotion in upstream and downstream areas of the vessel 
[6-9] and this may be associated with impaired endothelial regrowth. Although abnormal vasomotion would be 
considered undesirable, with potential to impair tissue perfusion distal to the stented region, it is rarely 
investigated during preclinical studies on novel drug-eluting stents. In this study we have implanted novel 
cicaprost-eluting stents in the iliac arteries of experimental rabbits. At 28 day follow-up we compared neointima 
formation as well as vascular function in adjacent vessels areas to assess if cicaprost could reduce restenosis 
without impairing vessel function. 
 
2. Methods 
 
2.1 Stent coating development  
 
Poly(L-lactide) (PLLA, 150kDa) was used as a polymer matrix to provide controlled release of cicaprost from 
the stent surface. A 1ml coating solution of 5% (w/v) PLLA:cicaprost (98:2) was prepared in chloroform. The 
formulation was selected to deliver cicaprost at a therapeutic dose, identified from our in vitro smooth muscle 
cell proliferation studies [19], and was based on a similar previously reported methodology that had achieved 
sustained release of iloprost and hirudin from a polymer coated stent [18].  Balloon mounted stents were 
immersed in this solution via a manual dipping process. Immersion times were approximately 1 second per 
coating. Two coatings were applied to each stent in this way, providing an average coating mass of 
DSSUR[LPDWHO\ȝg/stent (based on measurements from three separate stents with an average length of 16mm). 
A minimum of 12 hours was allowed for solvent evaporation to take place prior to stent implantation in vivo.  
 
2.2 In vivo stent implantation 
Animal care and all procedures conformed to the requirements of the U.K. Animals (Scientific Procedures) Act 
1986. The rabbit iliac artery model of stent injury has been previously characterised [21], and has been shown to 
have a range of prostanoid receptors, relevant to the assessment of PGI2 mediated effects [20]. Male New 
Zealand White rabbits (2.3-2.5kg; 11-13 weeks of age, sourced from Harlan; Cambridgeshire, UK) were 
premedicated with 1.2ml i.m. of Hypnorm® (fluanisone/fentanyl citrate mixture), 100mg i.m. of ampicillin 
suspension, and 500 units of heparin i.v. The animals were maintained throughout the procedure on a mixture of 
2% nitrous oxide and 1±1.5% isoflurane in oxygen. Stents (see Table 1) were introduced through the femoral 
artery using a 0.014in. steerable guidewire and implanted in the iliac artery under fluoroscopic guidance. The 
stent was deployed by inflating the balloon to a pressure sufficient to achieve a 1.1:1 stent:artery ratio. Pressure 
was maintained for a period of 30s, after which the balloon was deflated and withdrawn. The femoral artery was 
permanently ligated and the wound closed and sutured. All animals received oral aspirin (35mg) daily 
commencing one day before surgery, and for four days post-surgery. 
2.3 Rabbit artery removal and processing 
Rabbits were euthanized after 28 days by overdose of sodium pentobarbital.  The 28 day end point is in 
accordance with best practice [27] and our previous experience with this model, where we have observed 
marked neointima formation at this time point [21].  Iliac arteries were immediately dissected out, with sections 
PPSUR[LPDODQGGLVWDOWRWKHLPSODQWHGVWHQWEHLQJUHWDLQHGLQ.UHEV¶VROXWLRQIRUIXQFWLRQDOVWXGLHV6WHQWHG
artery sections were fixed in resin according to a previously published methodology [22]. Briefly, sections were 
placed in formal saline solution (24hrs), followed by acetone (24hrs) and infiltration solution (Technovit 8100, 
24 hrs), before being fixed in hardening solution for a minimum period of 24 hours at 4ºC. Hardened sections 
were cut using a diamond saw and polished using a rotary grinder (Buehler Isomet and Metaserv). Sections were 
stained with haematoxylin and eosin and an average of three sections from each artery (from proximal, middle, 
and distal sections) were prepared for planimetric analysis. 
2.4 Histological examination and analysis 
Stented artery sections were digitally photographed and the areas of key artery structures quantified using 
commercially available software (Image-Pro express). The areas bounded by the lumen, internal and external 
elastic laminae (IEL and EEL respectively), and neointima were quantified for each section. Percent vessel 
stenosis was calculated as follows: 
% stenosis =  100 x (1 ± (lumen area / IEL area)) 
Stent injury scores were calculated according to the method proposed by Gunn et al, where injury scores range 
from 0 to 4 depending on the degree of vessel stretch, and extent of damage to the internal and external elastic 
laminae [23]. Specifically, this scale ranges from no injury (0), through to stretch (1 or 2, depending on the 
angle of IEL deformation) and deep injury (3 (IEL ruptured) or 4 (EEL ruptured)). An individual injury score 
was assigned to each visible stent strut, with the average value of all stent struts being calculated for an 
individual artery section. All interpretation of strut injury scores and histological staining was performed in a 
blinded fashion.  
2.5 Vessel function study 
Isometric function studies were used to assess the effect of stent placement and local cicaprost elution on the 
function of nearby vasculature. 2-3mm artery rings were suspended between two intraluminal metal wires, one 
fixed with the other connected to an isometric force transducer. Following the establishment of consistent 
responses to two repeat doses of KCl (40mM), artery rings were exposed to cumulative additions of 
phenylephrine (10nM-ȝ0 (QGRWKHOLXP-dependent responses were assessed by cumulative addition of 
carbachol (10nM-ȝ0 IROORZLQJ SUH-FRQWUDFWLRQ WR SKHQ\OHSKULQH ȝ0 $ VLQJOH GRVH RI WKH
endothelium-independent vasodilator SIN- ȝ0 ZDV DGGHG WR WHVW VPRRWK PXVFOH UHVSRQVHV DW WKH HQG RI
each protocol.  
All data are presented as the mean ± one standard error of the mean. In artery function studies, statistically 
significant differences between curves were calculated using a two-way ANOVA using Graphpad Prism V4.0 
program. Where appropriate, best fit curves were applied to data sets using a linear regression sigmoidal dose 
UHVSRQVHFXUYHXVLQJ*UDSKSDG3ULVP$QXQSDLUHG6WXGHQW¶VW-test was used to compare in vivo data sets. In all 
cases differences were considered significant when the p value was less than 0.05.  
3 Results 
 
3.1 In vivo efficacy study 
 
The stent injury score was significantly greater in the cicaprost coated group compared to the bare metal control 
stents (Figure 1). Both the neointimal area and percentage stenosis were also found to be significantly greater in 
the cicaprost coated group.   
 
Figure 2 illustrates representative photomicrographs of stented artery sections. The vessel response to stent 
placement is characterised by moderate neointima formation in all bare metal stents (panels A, C, D and E), with 
greater levels of neointima found in the cicaprost group (B and F). In the cicaprost group, neointimal tissue 
growth of similar histological appearance to the tissue growth observed in the bare metal stent group was found 
in three out of the five stented vessels (panel B). In these three vessels, the neointimal tissue encroaches into the 
lumen (panel F). In the remaining two vessels in the cicaprost group, there was a distinct response with near 
complete occlusion of the vessel. 
 
3.2 Vessel Function Study 
 
Figure 3 details the results of the vessel function study. Bare metal stents had no significant effect on contractile 
(panel A) or endothelium-dependant relaxation (panel B) in distal sections compared to proximal sections. 
Cicaprost-coated stents significantly reduced contractile function in distal vessel sections compared to bare 
metal controls (panel E), with no difference being observed proximal to the stent (C). Endothelium-dependent 
relaxation was reduced both proximal (panel D) and distal to the cicaprost stent (F) compared to the bare metal 
stent, although the distal effect just failed to reach significance (p=0.0549). SIN- ȝ0SURGXFHG FRPSOHWH
relaxation in all vessels. 
 
4. Discussion  
 
It was our hypothesis that PGI2 analogues may represent promising compounds for use in drug-eluting stents by 
virtue of their unique biological profile; which includes inhibition of platelet activation, and smooth muscle cell 
proliferation. The present study is the first to report the effect of any PGI2 analogue alone, delivered locally 
from the stent surface, on neointima formation. 
 
At 28 days, we found that the neointimal area was significantly greater in vessels treated with a cicaprost-eluting 
stent compared to control stents. This is in contrast to what may have been predicted from in vitro studies, which 
have broadly demonstrated inhibitory effects on smooth muscle cell proliferation [14,15]. In vivo, although 
some negative results have been reported [24], PGI2 analogues have generally been shown to reduce restenosis 
in pig and rabbit models of balloon angioplasty without stent implantation [25,26]. Whilst differences exist, 
there is significant similarity in the mechanisms behind the neointima formation in balloon angioplasty and 
stenting. It may therefore have been expected that the generally positive results observed in angioplasty studies 
would have been maintained in the present study. Similarly, a stent releasing iloprost and hirudin in combination 
reduced neointima formation in the pig coronary artery [18]. There are several possible reasons for this apparent 
discrepancy in outcomes.   
 
Despite using a constant stent to vessel ratio of 1.1:1 throughout the study, a significant difference was observed 
in the stent injury scores between the bare metal control and the cicaprost coated stent group. The injury scores 
for both groups of 1.38 ± 0.04 (BMS) and 1.71 ± 0.08 (cicaprost) are comparable to the value of 1.74 reported in 
the pig coronary artery by Gunn et al [23] using the same scoring technique. It is well established that the extent 
of injury is a significant determinant of the subsequent degree of neointima formation observed [27]. A higher 
level of injury may therefore represent one factor responsible for the increased neointimal response observed in 
the cicaprost group.  
 
It is known that cicaprost has weak activity at prostanoid EP1 and EP3 receptors [20], and whilst we have SUHYLRXVO\GHPRQVWUDWHG WKDW FLFDSURVW LV VHOHFWLYH IRU WKH ,3 UHFHSWRUXS WRȝ0 in vitro [19], we have also 
observed that excess PGI2 analogue concentrations may activate EP1 and EP3 receptors, leading to 
vasoconstriction. Blindt has shown that EP3 receptor activation can lead to increased smooth muscle cell 
migration [28]. Therefore, high local cicaprost concentrations in the present study may have produced unwanted 
arterial constriction and stimulated increased smooth muscle cell migration. However, the extensive variety of 
prostanoid receptors and functions make interpretation of the in vivo data complex. In mice deficient in the 
prostanoid IP receptor there was increased thrombosis and increased inflammatory responses as evidenced by 
increased microvascular permeability [29]. The delivery of cicaprost may be sufficient to cause a significant 
disruption of the prostacyclin-thromboxane balance which is important in maintaining vascular haemostasis 
[30]. However, without data on the tissue concentration of cicaprost and how this varies over the 28 day follow-
up it is difficult to understand why cicaprost had such a negative effect on neointima formation. 
 
Our preliminary drug release studies using iloprost as a model PGI2 analogue demonstrated that 50% of the total 
iloprost released during the 14 day measuring period occurred within the first 24 hours (data not shown). Based 
on this, in vivo cicaprost release is likely to also occur rapidly, inhibiting the initial platelet aggregation at the 
site of arterial injury, and in so doing disrupt the normal vessel healing processes. This scenario may explain the 
failure to translate the generally positive results observed following balloon injury to stent placement, where the 
stent serves as a continuous stimulus to inflammation. As cicaprost release tails off, the presence of an unhealed 
vessel wall and stent may lead to a late platelet response and extensive neointima formation. A similar situation 
has been observed where platelet depletion for the first 14 days following endothelial denudation inhibited 
neointima formation, an effect which was reversed when fresh platelets were infused between 14 days and 28 
days in the rat carotid artery [31]. Because the concentration of cicaprost in tissue was not measured in vivo, it is 
not possible to determine whether the effects we observed were due to a toxic drug concentration. 
 
An alternative hypothesis is that the polymer coating was responsible for the dramatic increases in neointima 
produced by the cicaprost stent. Poly(L-lactide) (PLLA, 150kDa) was selected as the drug carrier for a number 
of reasons, including its reported biocompatibility. Poly(lactide) based polymers have been demonstrated to 
have minimal effect on restenosis in a number of animal studies [18,32], whilst a biodegradeable PLLA stent 
has been shown to be well tolerated in human coronary arteries [33]. However, PLLA (80kDa) can produce a 
severe inflammatory neointimal response and vessel occlusion in the pig coronary artery, whereas higher 
molecular weight PLLA (300kDa) was well tolerated [34]. It is therefore possible that the polymer induced a 
greater inflammatory response in the treatment group compared to the bare metal control; however we did not 
measure this in our study.  The change in surface characteristics caused by the polymer may also have had a 
negative impact on stenosis development. Such characteristics are an important determinant of the vessel 
reaction, with properties such as high surface energy and roughness being predictors of thrombosis formation 
[35]. In the present study it was observed that areas of the polymer coating between struts had potential to 
rupture following stent expansion, and hence decrease the uniformity and surface smoothness of the coating, 
which could act as a stimulus to increased thrombus formation. Equally, there was an uneven polymer 
distribution between struts. The deleterious effects of uneven polymer distribution have been highlighted 
previously [36]. The near complete vessel occlusion and severe disruption of normal arterial structures that we 
observed in 2 out of 5 cicaprost treated arteries, is consistent with the findings of this previous study [36]. 
Therefore, deleterious effects due to the PLLA polymer and its non-uniformity across the stent surface cannot be 
ruled out. 
 
In addition to incomplete endothelialisation, existing drug-eluting stents have been associated with endothelial 
cell dysfunction in surrounding artery sections [6-9]. In our study it was found that in arteries implanted with a 
bare metal stent, proximal and distal sections produced similar constrictive and relaxation responses. This 
finding is consistent with observations obtained clinically following bare metal stent placement, where no 
difference was found in distal artery responses to acetylcholine infusion [7]. Endothelium-dependent relaxation 
responses to carbachol in the cicaprost group were significantly reduced in proximal sections compared to bare 
metal controls, with a similar trend observed distally (p=0.0549). This suggests that the deleterious effect of the 
cicaprost stent placement on the endothelium may be independent of direction of blood flow, which is in 
contrast to the findings of Moses et al, 2003 [37]. They demonstrated a reduced neointima formation in distal 
stented sections compared to proximal stented sections following sirolimus-eluting stent placement, possibly 
supporting the hypothesis that drug elution tends to occur distal to the stent. However, our results are in 
agreement with the endothelial dysfunction demonstrated proximal and distal to a paclitaxel eluting stent [7] and 
this may indicate differences in how eluting drugs are affected by local physiological transport forces within the 
artery wall. Since there was no difference between endothelium-dependent responses proximal or distal artery 
tissue in the bare metal stent group, we can attribute this effect to the cicaprost stent itself, rather than an effect 
of the reduced blood supply due to severe stenosis and possible ischaemia. All artery sections produced 
complete relaxation following a single dose of SIN-1, suggesting that the medial layer function was unaltered by 
placement of either stent type. 
 
 
Conclusion 
 
This is the first study to report the effects of a novel polymer-coated cicaprost releasing stent. Our data indicate 
that PLLA-cicaprost coated stents have a deleterious effect on arterial recovery following injury. The high 
stenosis rate was possibly due to the polymer and a rapid release of cicaprost from the stent may have affected 
functional recovery of the endothelium in the adjacent artery. However, the precise mechanisms behind the 
failure of this novel stent remain to be elucidated. Further studies, most notably examining the direct effect of 
the polymer coating and of different drug loadings are therefore required. 
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Figures 
 
Figure 1.  Stent injury score, percent stenosis and neointimal area in the two treatment groups observed at 28 
days following stent placement in the rabbit iliac artery. *p<0.05 for cicaprost stent (n=5) versus bare metal 
stent (BMS) control (n=4).  
 
 
Figure 2.  Histological specimens stained with haematoxylin and eosin, highlighting typical results of in vivo 
stent placement in bare metal control (A) and cicaprost coated group (B). Small areas of neointimal tissue are 
evident around (C) and between stent struts (D and E) in the bare metal stent group. Classical neointima 
encroached into lumen within the cicaprost stent group (F). Panel A indicates the location of the key features, 
including the media, neointima, stent strut, the internal elastic lamina (IEL) and the lumen.  In panels C-F, the 
lumen lies on the right hand side of the image. Magnification levels were x20 (A and B) and x400 (C and D). 
Panels E and F are sections taken from a whole artery image obtained at x20 (shown as an insert) and 
subsequently resized to highlight key features of the original image.    
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 Figure 3.  Contractile function and endothelium-dependent relaxation in rabbit iliac artery sections proximal 
and distal to implanted stents. Stents were in situ for 28 days before arteries were removed for functional 
studies. Concentration-response curves to phenylephrine (A) and carbachol (B) did not differ in artery sections 
proximal and distal to bare metal stents. Concentration-response curves to phenylephrine in artery sections 
proximal (C), and distal (E) and to carbachol proximal (D) and distal (F) to the stent revealed that cicaprost-
eluting stents affected vessel function. n=4-5; *p<0.05 vs.bare metal stent 
 
  
Table 1 Stent platform and dimensions used for the two study groups.  
Study Group  Stent Platform 
Diameter 
(mm) 
Length 
(mm) 
Bare Metal Group (n=4) Liberte 2.5  8-16 
Cicaprost Stent Group (n=5) Mini-Vision 2.25-2.5 18-23 
 
